ASLAN Pharmaceuticals Limited logo
ASLAN Pharmaceuticals Limited ASLN

Annual report 2020
added 08-19-2023

report update icon

ASLAN Pharmaceuticals Limited EBITDA 2011-2026 | ASLN

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA ASLAN Pharmaceuticals Limited

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-33.8 M -16.5 M -45.6 M -42.3 M -39.1 M -8.58 M -12.8 M -7.28 M - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-7.28 M -45.6 M -25.8 M

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer EBITDA Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-508 M - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
-88.1 M - 1052.0 % $ 415 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
-14 M $ 2.3 -1.29 % $ 3.01 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-8.67 M - 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
-123 M - -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-65 M - 10.36 % $ 9.8 M usaUSA
I-Mab I-Mab
IMAB
13.8 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
3.11 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
31.8 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-26.8 M - -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-452 M $ 220.9 2.49 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
-62.4 M - -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-7 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-8.18 M - -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
172 M $ 19.57 1.77 % $ 915 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-16.2 M - - $ 26.5 M usaUSA
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
-159 M $ 10.47 4.08 % $ 763 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-37.3 M - - $ 7.46 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
-9.76 M - -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
-233 M - -24.86 % $ 820 K usaUSA
Atreca Atreca
BCEL
5.46 M - -11.76 % $ 5.79 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-16.7 M - 4.01 % $ 150 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
589 M - 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
-216 M - - $ 546 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
220 M - - - russiaRussia
Cara Therapeutics Cara Therapeutics
CARA
-121 M - -3.03 % $ 260 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-136 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-24.5 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
-35.9 M - -9.65 % $ 45.9 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
-155 M $ 1.31 2.34 % $ 80.4 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
-86.1 M $ 1.37 -1.44 % $ 72 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-11.3 M - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-234 M $ 1.33 0.76 % $ 339 M britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
-85.1 M $ 8.31 1.59 % $ 111 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
-645 M $ 47.09 1.42 % $ 4.23 B schweizSchweiz
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
-12 M - -5.98 % $ 34.1 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
-127 M - - $ 3.74 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
-103 M $ 3.26 4.49 % $ 251 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
505 K - - $ 2.02 B usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
-57.2 M $ 1.58 6.04 % $ 99.5 M niderlandNiderland
BioDelivery Sciences International BioDelivery Sciences International
BDSI
37.3 M - -4.8 % $ 255 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
-189 M - - $ 40.5 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-242 M - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-412 M - - $ 867 M germanyGermany
Palatin Technologies Palatin Technologies
PTN
-17.2 M $ 21.0 5.79 % $ 19.5 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-22.4 M - -74.18 % $ 955 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-285 M - - $ 3.67 B usaUSA
Pulmatrix Pulmatrix
PULM
-9.66 M $ 2.12 -1.4 % $ 7.74 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-37.8 M $ 4.53 5.1 % $ 868 M canadaCanada
Homology Medicines Homology Medicines
FIXX
17.3 M - 0.77 % $ 53.4 M usaUSA